Presenting SLEEK: a Highly Efficient Knock-In Technology for NextGeneration Cellular Medicines

Time: 8:50 am
day: Day Two


  • Illuminating a greater than 90% knock-in efficiency across clinically relevant cell types to ensure guaranteed robust expression of single and multiple transgene cargos
  • Demonstrating equal efficiency with both viral and non-viral DNA donor templates to provide a manufacturing advantage for enhanced scalability
  • Weaponizing the next generation of iPSC-derived NK cells (iNKs) with robust tumor killing and unprecedented persistence in vivo